The Use of Bromocriptine for Peripartum Cardiomyopathy after Twin Delivery via Oocyte Donation

Peripartum cardiomyopathy (PPCM) is rare but life-threatening. We herein report the case of a 48-year-old woman with PPCM after oocyte donation and delivery of twins. Two weeks after delivery, she suffered from severe symptoms of heart failure [orthopnea, New York Heart Association (NYHA) class IV, pulmonary edema and a reduced left ventricular ejection fraction of 18%]. Although standard heart failure therapy was effective for diminishing the congestion, it was not sufficient to improve her symptoms or left ventricular systolic dysfunction. During admission, we added bromocriptine. A year later after the onset, she was in a good state with an improved left ventricular systolic function.

[1]  A. Mebazaa,et al.  Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD , 2017, European heart journal.

[2]  K. Sliwa,et al.  Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study , 2017, European heart journal.

[3]  David F. Albertini,et al.  Systematic review of worldwide trends in assisted reproductive technology 2004–2013 , 2017, Reproductive Biology and Endocrinology.

[4]  J. Laven Primary Ovarian Insufficiency , 2016, Seminars in Reproductive Medicine.

[5]  F. Figueras,et al.  Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis , 2016, Journal of Assisted Reproduction and Genetics.

[6]  I. Goldenberg,et al.  Peripartum cardiomyopathy – risk factors, characteristics and long-term follow-up , 2014, Journal of perinatal medicine.

[7]  Young Seo Kim,et al.  Delayed ischemic stroke associated with bromocriptine-induced reversible cerebral vasoconstriction syndrome , 2013, Neurological Sciences.

[8]  T. Jernberg,et al.  Bromocriptine-Induced Coronary Spasm Caused Acute Coronary Syndrome, Which Triggered Its Own Clinical Twin – Takotsubo Syndrome , 2011, Cardiology.

[9]  K. Sliwa,et al.  Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy: A Proof-of-Concept Pilot Study , 2010, Circulation.

[10]  A. P. Walsh,et al.  IVF for premature ovarian failure: first reported births using oocytes donated from a twin sister , 2010, Reproductive biology and endocrinology : RB&E.

[11]  S. Lim,et al.  Preeclampsia: the role of angiogenic factors in its pathogenesis. , 2009, Physiology.

[12]  K. Sliwa,et al.  A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy , 2007, Cell.

[13]  I. Sargent,et al.  Latest Advances in Understanding Preeclampsia , 2005, Science.

[14]  U. Elkayam,et al.  Pregnancy-Associated Cardiomyopathy: Clinical Characteristics and a Comparison Between Early and Late Presentation , 2005, Circulation.

[15]  L. Schieve,et al.  Perinatal Outcome Among Singleton Infants Conceived Through Assisted Reproductive Technology in the United States , 2004, Obstetrics and gynecology.

[16]  J. Martial,et al.  The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. , 2003, Molecular endocrinology.

[17]  R. Carraway,et al.  Autoimmune mechanisms as the basis for human peripartum cardiomyopathy , 2002, Clinical reviews in allergy & immunology.

[18]  A. Moffett-King Natural killer cells and pregnancy , 2002, Nature Reviews Immunology.

[19]  M. E. King,et al.  Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. , 2002, American journal of obstetrics and gynecology.

[20]  C. Clapp,et al.  Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. , 2002, The Journal of endocrinology.

[21]  J. Hsia,et al.  Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. , 2000, JAMA.

[22]  L. Dragovic,et al.  Acute coronary artery thrombosis in a postpartum woman receiving bromocriptine. , 1998, The American journal of forensic medicine and pathology.

[23]  M. Faas,et al.  Why pre-eclampsia? , 1997 .

[24]  J. McArdle,et al.  Severe cerebral accidents postpartum in patients taking bromocriptine for milk suppression. , 1996, Israel journal of medical sciences.

[25]  L. Hopp,et al.  Acute myocardial infarction in a healthy mother using bromocriptine for milk suppression. , 1996, The Canadian journal of cardiology.

[26]  P. Devroey,et al.  Oocyte donation in patients without ovarian function. , 1988, Human reproduction.

[27]  S. Mazaki‐Tovi,et al.  The 'immunologic theory' of preeclampsia revisited: a lesson from donor oocyte gestations. , 2014, American journal of obstetrics and gynecology.

[28]  L. Pastore,et al.  Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. , 2004, Obstetrics and gynecology.

[29]  M. Faas,et al.  Why pre-eclampisa? , 1997, Human reproduction.

[30]  B. Sibai,et al.  Peripartum cardiomyopathy: an ominous diagnosis. , 1997, American journal of obstetrics and gynecology.

[31]  S. Jayalakshmi,et al.  Peripartum cardiomyopathy. , 1980, Journal of the Indian Medical Association.